Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT

Rocket Pharmaceuticals — Investor Presentation (November 2026)

36 slides from Rocket Pharmaceuticals's investor presentation, November 2026

  1. Slide 1: Rocket Pharmaceuticals Corporate Overview

    Slide 1: Rocket Pharmaceuticals Corporate Overview

    Rocket Pharmaceuticals Corporate Overview November 2026 © 2026 Rocket Pharmaceuticals

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    ABOUT ROCKET PHARMACEUTICALS DISCLAIMER This presentation contains forward -looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause actual results to

  3. Slide 3: Vision: Seeking Genetic Medicines Cures

    Slide 3: Vision: Seeking Genetic Medicines Cures

    ABOUT ROCKET PHARMACEUTICALS Vision: Seeking Genetic Medicines Cures Values Mission To develop first -in-class and best -in-class v Curiosity curative genetic Trust medicines for patients Elevate with life -threatening Generosity diseases 3 © 2026 Rocket Pharmaceuticals

  4. Slide 4: A Fully Integrated Cardiovascular Rare Disease Company

    Slide 4: A Fully Integrated Cardiovascular Rare Disease Company

    ABOUT ROCKET PHARMACEUTICALS A Fully Integrated Cardiovascular Rare Disease Company Integrated science, manufacturing and commercial capabilities to transform the lives of patients with life -threatening cardiovas cular diseases LATE -STAGE SCIENCE INTEGRATED EXPERIENCED FINANCIAL & INNOVATION MANUF

  5. Slide 5: Strong Science, Carefully-selected Assets and Smart Execution

    Slide 5: Strong Science, Carefully-selected Assets and Smart Execution

    ABOUT ROCKET PHARMACEUTICALS Strong Science, Carefully-selected Assets and Smart Execution Criteria used to select programs First -, best - and/or On -target MOA; Sizeable market to only -in-class clear endpoints maximize patient impact THERAPEUTIC PHASE 2 DISCOVERY PRECLINICAL PHASE 1 APPROVED DESI

  6. Slide 6: Rocket Offers Multi-platform Gene Therapy Expertise

    Slide 6: Rocket Offers Multi-platform Gene Therapy Expertise

    ABOUT ROCKET PHARMACEUTICALS Rocket Offers Multi -platform Gene Therapy Expertise IN VIVO platform EX VIVO platform Laboratory - Remove cells Laboratory - produced AAV and isolate produced LV patient HSCs Therapeutic AAV Therapeutic LV Infusion of modified Direct intravenous HSCs injection Gene -mod

  7. Slide 7: Well-Positioned as the Leader in Cardiovascular Genetic Medicines

    Slide 7: Well-Positioned as the Leader in Cardiovascular Genetic Medicines

    ABOUT ROCKET PHARMACEUTICALS Well-Positioned as the Leader in Cardiovascular Genetic Medicines Why Cardiomyopathy? Arrhythmogenic • High unmet medical need, current standard of care Cardiomyopathy focuses on symptom palliation and does not address root cause • One -time IV therapy with the potential

  8. Slide 8: Our Commitment to the Rare Disease Community

    Slide 8: Our Commitment to the Rare Disease Community

    ABOUT ROCKET PHARMACEUTICALS Our Commitment to the Rare Disease Community Allies and Partners in Global Focus Mission: Patient Advocacy GENOME No -Cost Genetic Investigational Counseling and Raising Gene Therapies Testing Awareness Market Inclusion of Research & Patient Epidemiology Perspectives S t

  9. Slide 9: Our R&D and Manufacturing Capabilities

    Slide 9: Our R&D and Manufacturing Capabilities

    ABOUT ROCKET PHARMACEUTICALS Our R&D and Manufacturing Capabilities • Total Lab Space: ~30,000 sq. ft. dedicated to R&D, process and analytical development, MS&T, and QC. • GMP Manufacturing Space: ~11,000 sq. ft. for multi -product clinical manufacturing with 2X expansion capability. • Manufacturin

  10. Slide 10: Danon Disease is a Highly Aggressive Rare Genetic Cardiomyopathy

    Slide 10: Danon Disease is a Highly Aggressive Rare Genetic Cardiomyopathy

    RP-A501: DANON DISEASE Danon Disease is a Highly Aggressive Rare Genetic Cardiomyopathy Danon Disease Clinical Manifestations Disease Etiology Impaired autophagy • X -linked, dominant, monogenic disease • Prominent • Myocardial disarray • Loss -of-function mutations in LAMP2 autophagic vacuoles Seve

  11. Slide 11: Estimated Epidemiology of Danon Disease is 20K+ across US & EU5

    Slide 11: Estimated Epidemiology of Danon Disease is 20K+ across US & EU5

    RP-A501: DANON DISEASE Estimated Epidemiology of Danon Disease is 20K+ across US & EU5 Independent genotype and phenotype -based analyses converge on similar estimate of 10 -11K US patients Genotype-Based Analysis Phenotype-Based Analysis Pathogenic & likely Pathogenic LAMP2 Variants Natural History

  12. Slide 12: Danon Disease can be Recognized Through Multiple Pathways

    Slide 12: Danon Disease can be Recognized Through Multiple Pathways

    RP-A501: DANON DISEASE Danon Disease can be Recognized Through Multiple Pathways Cardiac, multisystem, and family -based entry points can converge on a shared path to diagnosis and coordinated care MULTIPLE ENTRY POINTS RECOGNITION & REFERRAL GENETIC CONFIRMATION COORDINATED CARE Cardiac findings •

  13. Slide 13: Phase 1 and Phase 2 Study of RP-A501 in Danon Disease

    Slide 13: Phase 1 and Phase 2 Study of RP-A501 in Danon Disease

    RP-A501: DANON DISEASE Phase 1 and Phase 2 Study of RP-A501 in Danon Disease Global, single -arm, Pivotal Phase 2 Trial of RP -A501 ongoing; 12 -Patients aligned with FDA Phase 1: 3 years (completed) Pivotal Phase 2 (ongoing) 2 Adult/Adolescent (n=3) Adult/Adolescent (n=1) Current Status: Cohort 1 6

  14. Slide 14: RP-A501 Phase 1 Study: Sustained Cardiomyocyte LAMP2 Expression

    Slide 14: RP-A501 Phase 1 Study: Sustained Cardiomyocyte LAMP2 Expression

    RP-A501: DANON DISEASE RP-A501 Phase 1 Study: Sustained Cardiomyocyte LAMP2 Expression Durable myocardial LAMP2 protein expression seen in all patients Myocardial LAMP2 Protein Expression Representative LAMP2 IHC Images Cohort Patient BL M6 M12 M18 M24 M30 M36 M60 Pre -infusion Post -infusion Post -

  15. Slide 15: RP-A501 Phase 1: Benefit Observed Across All Key Parameters up to 7 years

    Slide 15: RP-A501 Phase 1: Benefit Observed Across All Key Parameters up to 7 years

    RP-A501: DANON DISEASE RP-A501 Phase 1: Benefit Observed Across All Key Parameters up to 7 years Lower cardiac biomarkers accompany stable or reduced LV mass index and improved quality -of -life scores Age at Most Δ NT -proBNP, Δ cTnI, † Δ LVMI,* Δ IVSd, Δ LVPWd, Δ NYHA Δ KCCQ -12, Cohort Patient Mo

  16. Slide 16: RP-A501 Phase 1 Summary

    Slide 16: RP-A501 Phase 1 Summary

    RP-A501: DANON DISEASE RP-A501 Phase 1 Summary LAMP2 expression and LVMI improvements seen as early as 6 months post RP -A501 Myocardial LAMP2 Protein Expression LVMI % Change: Baseline to 12m † Patient 1* Patient 2 Patient 3 Patient 4* Patient 6 Patient 7* M12 M18 † M18 † M12 M12 M12 -11% -16% -14%

  17. Slide 17: RP-A501 Pivotal Phase 2 Trial Design

    Slide 17: RP-A501 Pivotal Phase 2 Trial Design

    RP-A501: DANON DISEASE RP-A501 Pivotal Phase 2 Trial Design Pivotal, global, single -arm, open -label trial 1 Key eligibility criteria Co -Primary Endpoint Males age ≥8 years, LAMP2 To support accelerated approval, co - ✓ Cohort 1 -3 completed mutation, NYHA II -III, primary endpoint consisting of e

  18. Slide 18: Preliminary Efficacy of Phase 2 Study RP-A501: Up to 36 months

    Slide 18: Preliminary Efficacy of Phase 2 Study RP-A501: Up to 36 months

    RP-A501: DANON DISEASE Preliminary Efficacy of Phase 2 Study RP-A501: Up to 36 months Preliminary findings show stabilization or improvement in key disease measures Age at Most Δ LVMI, Δ NT -proBNP, Δ cTnI, Δ KCCQ -12 Δ IVSd , Δ LVPWd, Δ NYHA Cohort Patient Most RV Recent BL to RV BL to RV BL to RV

  19. Slide 19: Modified Protocol Delivers Favorable Pivotal Cohort 4 Safety Profile

    Slide 19: Modified Protocol Delivers Favorable Pivotal Cohort 4 Safety Profile

    RP-A501: DANON DISEASE Modified Protocol Delivers Favorable Pivotal Cohort 4 Safety Profile Grade ≥3 Serious Treatment Emergent Adverse Events Related to RP -A501 Phase 2 Cohorts 1 & 2 Cohort 3 Cohort 4 Pivotal Cohort 4 Preferred Term (Grade ≥3) (n=4) (n=2) (n=3) (recalibrated dose with modified IM

  20. Slide 20: No Evidence of TMA, CLS, or Other Severe Complement-Mediated Toxicities in Cohort 4

    Slide 20: No Evidence of TMA, CLS, or Other Severe Complement-Mediated Toxicities in Cohort 4

    RP-A501: DANON DISEASE No Evidence of TMA, CLS, or Other Severe Complement-Mediated Toxicities in Cohort 4 Platelets and Terminal Complement Complex (sC5b9) of the initial 3 patients up to 3 months post -treatment Patient 2 -7 Patient 2 -8 Patient 2 -9 Platelets Normal Range ‡ Complement Marker Norm

  21. Slide 21: Pivotal Phase 2 Trial of RP-A501 is Ongoing

    Slide 21: Pivotal Phase 2 Trial of RP-A501 is Ongoing

    RP-A501: DANON DISEASE Pivotal Phase 2 Trial of RP-A501 is Ongoing Phase 2/ Submission / Preclinical Phase 1 Pivotal Approval Phase 1 Safety & Efficacy Pivotal Phase 2 trial NEXT STEPS • Phase 1 clinical benefit observed up • Early Phase 2 results mirror Phase 1, • Dosing completion targeted for mid

  22. Slide 22: A Cardiomyopathy with High-Risk of Arrhythmias and Sudden Cardiac Death

    Slide 22: A Cardiomyopathy with High-Risk of Arrhythmias and Sudden Cardiac Death

    RP-A601: PKP2-ACM A Cardiomyopathy with High-Risk of Arrhythmias and Sudden Cardiac Death PKP2 -Arrhythmogenic Cardiomyopathy Clinical Manifestations (PKP2 -ACM) Disease Etiology Susceptibility 2 • Autosomal dominant mutations in PKP2 • Frequent and/or endurance exercise • Patients are often advised

  23. Slide 23: PKP2-ACM Prevalence in the US and EU

    Slide 23: PKP2-ACM Prevalence in the US and EU

    RP-A601: PKP2-ACM PKP2 -ACM Prevalence in the US and EU ACM prevalence 1:1000 to 1:5000 1,2 PKP2 variants 2,572 ACM patients assessed from 32.9% 13 publications an aggregated mean of 32.9% had PKP2 mutations 3 ACM -PKP2 US & EU Prevalence Utilizing the conservative ACM prevalence (1:5000) and the ~5

  24. Slide 24: Phase 1 Trial Design of RP-A601 in Adult Patients with PKP2-ACM

    Slide 24: Phase 1 Trial Design of RP-A601 in Adult Patients with PKP2-ACM

    RP-A601: PKP2-ACM Phase 1 Trial Design of RP -A601 in Adult Patients with PKP2 -ACM First -in-human, multi -center, o pen -label, dose escalation trial 1 Starting Dose (RP -A601): Safety and Efficacy Long -Term Follow -Up 8 x 10 13 GC/kg (IV) Assessments Yearly Safety Monitoring Month Month Month Mo

  25. Slide 25: Preliminary Indications of Improvement or Stabilization with RP-A601

    Slide 25: Preliminary Indications of Improvement or Stabilization with RP-A601

    RP-A601: PKP2-ACM Preliminary Indications of Improvement or Stabilization with RP-A601 in Clinical Markers of Arrhythmia Burden, Heart Function and QoL Heart Function & QoL Arrhythmia Burden RV Systolic T -wave Age at Most Recent KCCQ -12 Function NYHA Class PVCs per 24h NSVTs per 24h inversions Pat

  26. Slide 26: Ongoing FDA Engagement for RP-A601 in PKP2-ACM

    Slide 26: Ongoing FDA Engagement for RP-A601 in PKP2-ACM

    RP-A601: PKP2-ACM Ongoing FDA Engagement for RP-A601 in PKP2-ACM Phase 2/ Submission / Preclinical Phase 1 Pivotal Approval Phase 1 Safety Phase 1 Efficacy NEXT STEPS • RP -A601 was generally • All 3 patients demonstrated cardiac transduction with • With no further dose escalation plans, well -toler

  27. Slide 27: Cardiovascular Health is Dependent on Functional BAG3 Protein

    Slide 27: Cardiovascular Health is Dependent on Functional BAG3 Protein

    RP-A701: BAG3-DCM Cardiovascular Health is Dependent on Functional BAG3 Protein BAG3 -Dilated Cardiomyopathy Disease Etiology (BAG3 -DCM) • Autosomal dominant mutations in BAG3 gene • Loss of BAG3 leads to an accumulation of misfolded and damaged proteins, which impairs the heart’s ability to contra

  28. Slide 28: BAG3-DCM Patients are at High Risk of Progression to End Stage Disease

    Slide 28: BAG3-DCM Patients are at High Risk of Progression to End Stage Disease

    RP-A701: BAG3-DCM BAG3-DCM Patients are at High Risk of Progression to End Stage Disease Clinical Manifestations Dilated cardiomyopathy (DCM) • Characterized by progressive thinning of • Impairment of the heart’s ability to contract, the walls of the heart, causing dysfunction of leads to impaired c

  29. Slide 29: RP-A701 Restores Cardiac Function Dose-Dependently in a BAG3-KO Mouse Model

    Slide 29: RP-A701 Restores Cardiac Function Dose-Dependently in a BAG3-KO Mouse Model

    RP-A701: BAG3-DCM RP-A701 Restores Cardiac Function Dose-Dependently in a BAG3-KO Mouse Model1 Restoration of Cardiac Protein Expression Human BAG3 Protein Expression HSPB8 Protein Expression Profibrotic Marker Col1a1 15000 120 **** Arbitrary Unit (Western Blot) ✱✱ ✱ • AAVrh.74 -BAG3 produced dose -

  30. Slide 30: Phase 1 Trial Design of RP-A701 in Adult Patients with BAG3-DCM

    Slide 30: Phase 1 Trial Design of RP-A701 in Adult Patients with BAG3-DCM

    RP-A701: BAG3-DCM Phase 1 Trial Design of RP-A701 in Adult Patients with BAG3-DCM First-in-human, open-label, dose escalation trial1 Dose of RP -A701 Safety and Efficacy (IV) Long -Term Follow -Up Assessments Yearly Safety Monitoring Month Month Month Month Month Month Month ≥60 0 3 6 9 12 18 24 Mon

  31. Slide 31: Severe LAD-I: A Life-Threatening Pediatric Genetic Immune Disorder

    Slide 31: Severe LAD-I: A Life-Threatening Pediatric Genetic Immune Disorder

    KRESLADI : Severe LAD-I Severe LAD-I: A Life-Threatening Pediatric Genetic Immune Disorder Severe Leukocyte Adhesion Clinical Manifestations Deficiency -I (LAD -I) 1,2 Disease Etiology Patients suffer from severe, recurrent infections; fatal in majority • ITGB2 gene mutations (21q22.3), encoding • A

  32. Slide 32: KRESLADI received FDA accelerated approval

    Slide 32: KRESLADI received FDA accelerated approval

    32 *KRESLADI received FDA accelerated approval based on CD18 and CD11a surface expression. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). © 2026 Rocket Pharmaceuticals

  33. Slide 33: KRESLADI Ready for First Commercial Patient Enrollment

    Slide 33: KRESLADI Ready for First Commercial Patient Enrollment

    KRESLADI : Severe LAD-I KRESLADI Ready for First Commercial Patient Enrollment Commercial Patient Enrollment Now Open • Rocket achieved commercial readiness for KRESLADI on October 1, 2026. • Two Qualified Treatment Center s (QTCs) are activated , and Rocket is ready to begin Approximately 25 childr

  34. Slide 34: Wave 2: Future Cardiovascular Gene Therapies

    Slide 34: Wave 2: Future Cardiovascular Gene Therapies

    FUTURE DIRECTIONS Wave 2: Future Cardiovascular Gene Therapies Current programs reflect only the tip of the iceberg – Disciplined focus today for scalable innovation tomorrow. Focused R&D Strategy Above the Surface: for Sustainable Innovation Current Clinical Pipeline First -, Best - and/or Only -in

  35. Slide 35: Expert Leadership With Proven Track Record

    Slide 35: Expert Leadership With Proven Track Record

    ABOUT ROCKET PHARMACEUTICALS Expert Leadership With Proven Track Record Gaurav Shah, M.D. Sarbani Chaudhuri Syed Rizvi , M.D. Chief Executive Officer Chief Commercial Officer Chief Medical Officer 20+ years of experience driving 20+ years of experience Spearheaded Kymriah commercial growth for rare

  36. Slide 36

    Slide 36

Source: company website

More decks from Rocket Pharmaceuticals, Inc.

All 44 Rocket Pharmaceuticals decks